| scholarly article | Q13442814 |
| P50 | author | Moriya Tsuji | Q37842009 |
| P2093 | author name string | Guangli Yang | |
| Richard W Franck | |||
| John Schmieg | |||
| P2860 | cites work | Convergent C-glycolipid synthesis via the Ramberg-Bäcklund reaction: active antiproliferative glycolipids | Q73846224 |
| Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors | Q73889862 | ||
| Synthesis and growth inhibitory properties of glucosamine-derived glycerolipids | Q74110089 | ||
| A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system | Q77929123 | ||
| Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells | Q78336930 | ||
| A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors | Q78632792 | ||
| CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides | Q28254991 | ||
| NKT cells: facts, functions and fallacies. | Q34091324 | ||
| Immunotherapy with ligands of natural killer T cells | Q34688305 | ||
| Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo | Q35168204 | ||
| The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion | Q35978664 | ||
| Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers | Q36361001 | ||
| Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers | Q36368804 | ||
| CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution | Q36404242 | ||
| alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria | Q37229005 | ||
| Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology | Q41039639 | ||
| Mouse CD1-specific NK1 T cells: development, specificity, and function | Q41464349 | ||
| The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells | Q41815553 | ||
| A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells | Q43756252 | ||
| Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. | Q44146651 | ||
| Synthesis of homoceramides, novel ceramide analogues, and their lack of effect on the growth of hippocampal neurons | Q45713713 | ||
| Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation. | Q52023804 | ||
| Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. | Q52525223 | ||
| Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. | Q53963043 | ||
| Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells | Q59387569 | ||
| Sequential production of interferon-gamma by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of alpha -galactosylceramide | Q60489559 | ||
| Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice | Q72317791 | ||
| Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells | Q73098737 | ||
| Requirement for IFN-gamma in IL-12 production induced by collaboration between v(alpha)14(+) NKT cells and antigen-presenting cells | Q73250789 | ||
| Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells | Q73311971 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| (1R)-1,5-anhydro-1-[(3S,4S,5R)-3-(hexacosanoylamino)-4,5-dihydroxynonadecyl]-D-galactitol | Q27225773 | ||
| P304 | page(s) | 1631-1641 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide | |
| P478 | volume | 198 |
| Q27667168 | A Molecular Basis for the Exquisite CD1d-Restricted Antigen Specificity and Functional Responses of Natural Killer T Cells |
| Q41165520 | A Solvent-free Approach to Glycosyl Amides: Towards the Synthesis of α-N-Galactosyl Ceramides |
| Q37644961 | A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity |
| Q33570532 | A multifactorial mechanism in the superior antimalarial activity of alpha-C-GalCer |
| Q33852300 | A rapid fluorescence-based assay for classification of iNKT cell activating glycolipids |
| Q37491277 | A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens |
| Q34287659 | Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection |
| Q55398868 | Activation and Regulation of B Cell Responses by Invariant Natural Killer T Cells. |
| Q37002932 | Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses |
| Q27318814 | Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis |
| Q53262191 | Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis. |
| Q38908501 | Activation strategies for invariant natural killer T cells |
| Q41639759 | Adjuvant effects of therapeutic glycolipids administered to a cohort of NKT cell-diverse pigs |
| Q30377447 | Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. |
| Q41763024 | Alpha-S-GalCer: synthesis and evaluation for iNKT cell stimulation |
| Q34172161 | Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection |
| Q33877217 | Alpha-galactosylceramide promotes killing of Listeria monocytogenes within the macrophage phagosome through invariant NKT-cell activation |
| Q42257577 | Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production |
| Q61986624 | Aminocyclitol-Substituted Phytoceramides and their Effects on iNKT Cell Stimulation |
| Q43634902 | An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine |
| Q26751343 | Antigen specificity of invariant natural killer T-cells |
| Q34338958 | Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency |
| Q39377809 | Beta-glucosylceramide administration (i.p.) activates natural killer T cells in vivo and prevents tumor metastasis in mice |
| Q35761273 | Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders |
| Q36474450 | Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants |
| Q24625835 | C-galactosylceramide: Synthesis and immunology |
| Q37187358 | CD1d presentation of glycolipids |
| Q90259266 | CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond |
| Q36898124 | CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system |
| Q47927252 | Characterization and Functional Analysis of Mouse Semi-invariant Natural T Cells |
| Q53554033 | Characterizing host immune responses by monitoring fluorescently marked cells. |
| Q38115508 | Chemical tools for studying the biological function of glycolipids |
| Q37824065 | Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant |
| Q38564323 | Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses |
| Q34039891 | Cytokine dependent and independent iNKT cell activation |
| Q92093422 | Design and efficient synthesis of pyrazoline and isoxazole bridged indole C-glycoside hybrids as potential anticancer agents |
| Q39955940 | Design, synthesis, and functional activity of labeled CD1d glycolipid agonists |
| Q35850748 | Distinct APCs explain the cytokine bias of α-galactosylceramide variants in vivo. |
| Q34103244 | Distinct and overlapping effector functions of expanded human CD4+, CD8α+ and CD4-CD8α- invariant natural killer T cells |
| Q34626935 | Diverse roles of non-diverse molecules: MHC class Ib molecules in host defense and control of autoimmunity |
| Q53077248 | Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity. |
| Q40860044 | Editorial: CD1- and MR1-Restricted T Cells in Antimicrobial Immunity |
| Q40513167 | Eliciting Epitope-Specific CD8+ T Cell Response by Immunization with Microbial Protein Antigens Formulated with α-Galactosylceramide: Theory, Practice, and Protocols |
| Q36249071 | Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes |
| Q39633103 | Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses |
| Q33436168 | Establishment of mass spectrometric fingerprints of novel synthetic cholesteryl neoglycolipids: the presence of a unique C-glycoside species during electrospray ionization and during collision-induced dissociation tandem mass spectrometry |
| Q42972264 | Functionally distinct NKT cell subsets and subtypes |
| Q55318324 | Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control. |
| Q27667759 | Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis |
| Q34479554 | Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells |
| Q38885794 | Glycolipid activators of invariant NKT cells as vaccine adjuvants |
| Q34983932 | Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice |
| Q37187603 | Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants |
| Q33762686 | Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion |
| Q36407438 | Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers |
| Q36517889 | Glycolipids as immunostimulating agents |
| Q27676395 | Glycolipids that Elicit IFN-γ-Biased Responses from Natural Killer T Cells |
| Q35951531 | Going both ways: immune regulation via CD1d-dependent NKT cells |
| Q42668044 | Harnessing CD1d-restricted T cells toward antitumor immunity in humans |
| Q48343602 | Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective |
| Q37388427 | Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges |
| Q37349692 | Harnessing invariant NKT cells in vaccination strategies |
| Q36584187 | How T lymphocytes recognize lipid antigens |
| Q24650966 | How do natural killer T cells help B cells? |
| Q39859712 | Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells |
| Q36637517 | Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells |
| Q37565143 | Human invariant natural killer T cells: implications for immunotherapy |
| Q39863367 | Human leukemic cells loaded with alpha-galactosylceramide (alpha-GalCer) activate murine NKT cells in situ |
| Q33267309 | Human natural killer T cells are heterogeneous in their capacity to reprogram their effector functions |
| Q39843991 | Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells |
| Q38079152 | Imaging natural killer T cells in action |
| Q38890717 | Immunotherapeutic strategies targeting natural killer T cell responses in cancer. |
| Q28543248 | Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells |
| Q38942602 | In vivo antimalarial activities of glycoalkaloids isolated from Solanaceae plants |
| Q37286356 | Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin |
| Q39735626 | Induction of Th1-biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells |
| Q34429040 | Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity |
| Q36404025 | Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells |
| Q36990616 | Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity |
| Q48316500 | Innate immune cells for immunotherapy of autoimmune and cancer disorders. |
| Q36251325 | Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania |
| Q37822744 | Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens |
| Q36799695 | Invariant NKT cells and tolerance |
| Q21284987 | Invariant NKT cells as novel targets for immunotherapy in solid tumors |
| Q28083069 | Invariant natural killer T cells and their ligands: focus on multiple sclerosis |
| Q38120169 | Invariant natural killer T cells in adipose tissue: novel regulators of immune-mediated metabolic disease. |
| Q37686081 | Invariant natural killer T cells in rheumatic disease: a joint dilemma |
| Q34323476 | Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions |
| Q36739848 | Invariant natural killer T cells: bridging innate and adaptive immunity |
| Q36895646 | Invariant natural killer cells in the response to bacteria: the advent of specific antigens |
| Q37285947 | Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation |
| Q35837120 | Lipid and Carbohydrate Modifications of α-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation |
| Q33724575 | Lipid and glycolipid antigens of CD1d-restricted natural killer T cells |
| Q37219070 | Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen alphaGalCer |
| Q27658388 | Mechanisms for Glycolipid Antigen-Driven Cytokine Polarization by V 14i NKT Cells |
| Q39702161 | Methylene Homologues of Artemisone: An Unexpected Structure-Activity Relationship and a Possible Implication for the Design of C10-Substituted Artemisinins |
| Q33927443 | Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides |
| Q38050484 | Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells |
| Q36224039 | Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer |
| Q34519826 | Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity |
| Q33653495 | Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity |
| Q41138405 | NK and NKT Cell Depletion Alters the Outcome of Experimental Pneumococcal Pneumonia: Relationship with Regulation of Interferon-γ Production |
| Q27674653 | NKT TCR Recognition of CD1d- -C-Galactosylceramide |
| Q36568780 | NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma |
| Q26866223 | NKT cell networks in the regulation of tumor immunity |
| Q39128707 | Nanomapping of CD1d-glycolipid complexes on THP1 cells by using simultaneous topography and recognition imaging. |
| Q47221129 | Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective |
| Q35506478 | Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice |
| Q38148759 | Natural killer T cell based Immunotherapy |
| Q36521991 | Natural killer T cell-mediated antitumor immune responses and their clinical applications |
| Q37545341 | Natural killer T cells and the regulation of asthma |
| Q35798168 | Natural killer T cells as targets for immunotherapy of autoimmune diseases |
| Q36765720 | Natural killer T cells in health and disease |
| Q36799698 | Natural killer T cells regulate the development of asthma |
| Q42579685 | Natural killer T cells subsets in cancer, functional defects in prostate cancer and implications for immunotherapy |
| Q34605137 | Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. |
| Q36969739 | Natural killer T-cell autoreactivity leads to a specialized activation state |
| Q42608724 | Non-glycosidic compounds can stimulate both human and mouse iNKT cells |
| Q50095531 | Non-specific CD8+ T cells and dendritic cells/macrophages participate in CD8+ T cell-mediated cluster formation against malaria liver-stage infection. |
| Q35925629 | Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma |
| Q38206819 | Optimizing NKT cell ligands as vaccine adjuvants |
| Q33318487 | Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules |
| Q63361216 | Photoactivable Glycolipid Antigens Generate Stable Conjugates with CD1d for Invariant Natural Killer T Cell Activation |
| Q35973205 | Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids |
| Q42954809 | Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis |
| Q34761156 | Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model |
| Q95383075 | Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist |
| Q64076705 | Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy |
| Q38639439 | Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis |
| Q35684305 | Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production |
| Q37088000 | Recognition of CD1d-restricted antigens by natural killer T cells |
| Q34000070 | Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ. |
| Q28256001 | Regulation of interferon-gamma during innate and adaptive immune responses |
| Q36139773 | Regulation of the actin cytoskeleton by Rho kinase controls antigen presentation by CD1d. |
| Q37834024 | Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis |
| Q55365683 | Role of Natural Killer T Cells in the Development of Obesity and Insulin Resistance: Insights From Recent Progress. |
| Q40556221 | Selective Conditions Are Required for the Induction of Invariant NKT Cell Hyporesponsiveness by Antigenic Stimulation |
| Q38844616 | Small-Molecule Carbohydrate-Based Immunostimulants. |
| Q33599059 | Stimulation of natural killer T cells by glycolipids |
| Q47745185 | Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity |
| Q38016483 | Strategy of lipid recognition by invariant natural killer T cells: 'one for all and all for one'. |
| Q27677017 | Structural and Functional Characterization of a Novel Nonglycosidic Type I NKT Agonist with Immunomodulatory Properties |
| Q84938053 | Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice |
| Q54643220 | Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide. |
| Q38862782 | Synthesis and biological activities of C-glycosides of KRN 7000 with novel ceramide residues |
| Q48213664 | Synthesis of C6''-modified α-C-GalCer analogues as mouse and human iNKT cell agonists |
| Q42160618 | Synthesis of a versatile building block for the preparation of 6-N-derivatized α-galactosyl ceramides: rapid access to biologically active glycolipids |
| Q26748456 | Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents |
| Q39196835 | Tailored design of NKT-stimulatory glycolipids for polarization of immune responses |
| Q37995950 | Targeting natural killer cells and natural killer T cells in cancer |
| Q37874633 | Targeting the diverse immunological functions expressed by hepatic NKT cells |
| Q35860595 | The Alpha and Omega of Galactosylceramides in T Cell Immune Function |
| Q38883512 | The CD1 family: serving lipid antigens to T cells since the Mesozoic era. |
| Q26797344 | The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell Generation |
| Q55094012 | The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach. |
| Q37484801 | The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition |
| Q38611633 | The burgeoning family of unconventional T cells |
| Q34328138 | The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells |
| Q42661990 | The crystal structure of human CD1d with and without alpha-galactosylceramide |
| Q34179888 | The effect of intracellular trafficking of CD1d on the formation of TCR repertoire of NKT cells |
| Q36799681 | The in vivo response of invariant natural killer T cells to glycolipid antigens |
| Q37762343 | The invariant NKT cell subset in anti-viral defenses: a dark horse in anti-influenza immunity? |
| Q27023425 | The regulatory role of invariant NKT cells in tumor immunity |
| Q24648939 | The role of NKT cells in tumor immunity |
| Q38090560 | The role of natural killer T cells in B cell malignancies |
| Q33843406 | The stimulating adventure of KRN 7000. |
| Q53050285 | The synthesis and in vivo evaluation of 2',2'-difluoro KRN7000. |
| Q36799691 | Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases |
| Q58777562 | Tissue-Specific Roles of NKT Cells in Tumor Immunity |
| Q37137098 | Toll-like receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes |
| Q41841063 | Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric α-galactosyl ceramide analogues |
| Q35879532 | Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease |
| Q35998799 | alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles |
| Q33778356 | Α-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents |
| Q57598595 | α-GalCer ameliorates listeriosis by accelerating infiltration of Gr-1+ cells into the liver |
| Q93062542 | α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials |
| Q59134498 | α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma |
Search more.